Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



ELI LILLY AND COMPANY Hits Price Target Forecast with 26.14% Profit

May 01, 2023
ELI LILLY AND COMPANY's stock reached the forecasted price target of 398.15 $ on May 1, 2023, as predicted by QuantWave on July 1, 2022. This successful forecast resulted in a profit of 26.14% for investors who followed the long signal. The achievement of this forecast showcases the accuracy and reliability of QuantWave's analytics in predicting stock movements.

Market analysis indicates that ELI LILLY AND COMPANY has been benefiting from strong financial performance and a positive outlook in the pharmaceutical industry. Factors contributing to the stock's movement may include successful product launches, strategic partnerships, and continued innovation in healthcare solutions. The broader context of this forecast success highlights the potential for investors to make informed decisions and generate profits using QuantWave's automated forecasting platform.

QuantWave offers users access to predictions for a wide range of stocks, presenting opportunities for potential profits based on data-driven insights. For a deeper understanding of investment strategies, QuantSchool provides comprehensive educational resources to guide users in utilizing the QuantWave forecasting system effectively. By leveraging QuantWave's predictive capabilities and QuantSchool's investment framework, investors can aim to achieve consistent income and enhance their portfolio performance.
If you want to leave a comment, then you need Login or Register





Other data for LLY

Related data

LLYAugust 12, 2025Eli Lilly and Co LLY Traded Lower in Q2 Despite Good Results  ~1 min.

Eli Lilly and Company, despite reporting good results in the second quarter of this year, saw its stock price traded lower....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Forecasted Price Target with 20.09% Profit: QuantWave Achieves Success  ~1 min.

On January 28, 2025, QuantWave, an automated forecasting platform, issued a short signal for ELI LILLY AND COMPANY stock when it was trading at 800.2 $....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Price Target, Generating 18.65% Profit for QuantWave Users  ~1 min.

ELI LILLY AND COMPANY's stock recently reached the price target forecasted by QuantWave on 2024-08-06. The forecast signal indicated a short position, with the stock priced at 786.06 $....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Short Price Target Forecast Resulting in 19.15% Profit for QuantWave Users  ~2 min.

ELI LILLY AND COMPANY (LLY) investors recently saw the stock hitting a short price target forecast set by QuantWave, resulting in a substantial profit of 19.15%....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Price Target Resulting in 19.55% Profit - QuantWave Success  ~1 min.

ELI LILLY AND COMPANY stock has successfully reached the price target as forecasted by QuantWave, resulting in a profitable 19.55% gain for investors....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits QuantWave Forecast, Delivering 19.57% Profit  ~1 min.

ELI LILLY AND COMPANY has achieved the price target forecast set by QuantWave, signaling a 19.57% profit for investors....


LLYAugust 7, 2025ELI LILLY AND COMPANY Stock Hits Forecasted Price Target with 22.51% Profit  ~1 min.

ELI LILLY AND COMPANY stock recently achieved its forecasted price target as predicted by QuantWave, a leading automated forecasting platform....


LLYAugust 7, 2025ELI LILLY AND COMPANY Hits Forecast Price Target with 22.13% Profit on QuantWave Platform  ~2 min.

ELI LILLY AND COMPANY (LLY) recently achieved the forecast price target on the QuantWave platform, resulting in a remarkable 22.13% profit for investors who followed the short signal....


LLYAugust 1, 2025Eli Lilly and Company Completes Acquisition of Verve Therapeutics, Advancing One-Time Treatments for High Cardiovascular Risk  ~1 min.

Eli Lilly and Company has announced the successful completion of its acquisition of Verve Therapeutics, a move that will help advance innovative one-time treatments for individuals with high cardiovascular risk. This strategic decision showcases the company's commitment to revolutionizing the healthcare industry and improving patient outcomes. Investors are eagerly watching as Eli Lilly continues ...


LLYJuly 20, 2025Strong Q2 Forecast for ELI LILLY AND COMPANY by J.P. Morgan  ~1 min.

According to J.P. Morgan, Eli Lilly and Company is expected to have a strong second quarter performance. The pharmaceutical giant has been receiving positive attention from investors and analysts alike....


REGNFebruary 9, 2025Regeneron Pharmaceuticals Inc REGN Reports Strong Earnings in Q4 2024  ~2 min.

Regeneron Pharmaceuticals Inc., a leading biotechnology company, announced its impressive financial results for the fourth quarter of 2024....


PFEJune 6, 2025PFIZER INC. PFE Partners with Acepodia, Innovating Cancer Treatments  ~1 min.

Pfizer Inc. announced a new partnership with Acepodia to develop cutting-edge cancer treatments....


REGNOctober 13, 2022REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 22.38% Profit: QuantWave's Success  ~2 min.

On August 4, 2022, QuantWave issued a long signal for REGENERON PHARMACEUTICALS, INC. with a price target of $749.35. The stock, which was at $612....


ABBVFebruary 6, 2024ABBVIE INC. Achieves Price Target Forecast with 19.2% Profit on QuantWave Platform  ~1 min.

QuantWave, an automated forecasting platform, celebrated another successful prediction as ABBVIE INC. reached its forecasted price target of 165.67 $ on 2024-02-06. This achievement represents a 19....


AZNDecember 4, 2024AstraZeneca PLC - A Promising Investment Opportunity for ADR Stocks  ~2 min.

AstraZeneca PLC (AZN) is making waves in the pharmaceutical industry with its groundbreaking research and innovative drug development....